Content deleted Content added
add template |
no longer a stub |
||
| (23 intermediate revisions by 10 users not shown) | |||
Line 1:
{{Short description|Chemical compound}}
{{Use American English|date=February 2021}}
{{Use dmy dates|date=February 2021}}
{{Infobox drug
| image = Trilaciclib.svg
| width =
Line 11 ⟶ 9:
<!-- Clinical data -->
| pronounce = {{IPAc-en|ˌ|t|r|aɪ|l|ə|ˈ|s|aɪ|k|l|ɪ|b}}<br />{{respell|TRY|lə|SY|klib}}
| tradename = Cosela
| Drugs.com = {{drugs.com|pro|Cosela}}
| MedlinePlus =
| DailyMedID = Trilaciclib
| pregnancy_
| pregnancy_
| pregnancy_category=
| routes_of_administration = [[Intravenous]]
| class = [[CDK inhibitor|Cyclin-dependent kinase (CDK) inhibitor]]
|
|
| ATC_supplemental =
Line 44 ⟶ 37:
| legal_UK_comment =
| legal_US = Rx-only
| legal_US_comment = <ref name="Cosela FDA label">{{cite web | title=Cosela- trilaciclib injection, powder, lyophilized, for solution | website=DailyMed | url=https://
| legal_EU =
| legal_EU_comment =
Line 65 ⟶ 58:
| CAS_number = 1374743-00-6
| CAS_supplemental =
| PubChem = 68029831
| IUPHAR_ligand =
| DrugBank_Ref =
Line 84 ⟶ 77:
<!-- Chemical and physical data -->
| IUPAC_name = 4-[<nowiki/>[5-(4-methylpiperazin-1-yl)pyridin-2-yl]amino]spiro[1,3,5,11-tetrazatricyclo[7.4.0.0<sup>2,7</sup>]trideca-2,4,6,8-tetraene-13,1'-cyclohexane]-10-one
| C = 24 | H = 30 | N = 8 | O = 1
| SMILES = CN1CCN(CC1)C1=CN=C(NC2=NC3=C(C=C4N3C3(CCCCC3)CNC4=O)C=N2)C=C1
Line 102 ⟶ 95:
}}
'''Trilaciclib''', sold under the brand name '''Cosela''', is a [[medication]] used to reduce the frequency of chemotherapy-induced bone marrow suppression.<ref name="Cosela FDA label" /><ref name="FDA PR">{{cite press release | title=FDA Approves Drug to Reduce Bone Marrow Suppression Caused by Chemotherapy | website=U.S. [[Food and Drug Administration]] (FDA) | date=12 February 2021 | url=https://www.fda.gov/news-events/press-announcements/fda-approves-drug-reduce-bone-marrow-suppression-caused-chemotherapy | access-date=12 February 2021}} {{PD-notice}}</ref><ref>{{cite press release | title=FDA Approves G1
The most common side effects include fatigue; low levels of calcium, potassium and phosphate; increased levels of an enzyme called aspartate aminotransferase; headache; and infection in the lungs (pneumonia).<ref name="FDA PR" />
Trilaciclib may help protect bone marrow cells from damage caused by chemotherapy by inhibiting [[cyclin-dependent kinase]] 4/6, a type of enzyme.<ref name="FDA PR" /> Trilaciclib is the first therapy in its class and was approved for medical use in the United States in February 2021.<ref name="FDA PR"/><ref>{{cite web | title=Drug Approval Package: Cosela | website=U.S. [[Food and Drug Administration]] (FDA) | date=12 March 2021 | url=https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/214200Orig1s000TOC.cfm | access-date=13 September 2021}}</ref> The U.S. [[Food and Drug Administration]] considers it to be a [[first-in-class medication]].<ref name="New Drug Therapy Approvals 2021">{{cite report | title=Advancing Health Through Innovation: New Drug Therapy Approvals 2021 | website=U.S. [[Food and Drug Administration]] (FDA) | date=13 May 2022 | url=https://www.fda.gov/media/155227/download | format=PDF | access-date=22 January 2023 | archive-date=6 December 2022 | archive-url=https://web.archive.org/web/20221206210020/https://www.fda.gov/media/155227/download | url-status=live }} {{PD-notice}}</ref>
Chemotherapy drugs are designed to kill cancer cells but can damage normal tissues as well.<ref name="FDA PR" /> The bone marrow is particularly susceptible to chemotherapy damage.<ref name="FDA PR" /> The bone marrow makes red blood cells, white blood cells, and platelets (small fragments in the blood) that transport oxygen, fight infection, and stop bleeding.<ref name="FDA PR" /> When damaged, the bone marrow produces fewer of these cells, leading to fatigue, increased risk of infection, and bleeding, among other problems.<ref name="FDA PR" /> Trilaciclib may help protect the normal bone marrow cells from the harmful effects of chemotherapy.<ref name="FDA PR" />
Line 123 ⟶ 116:
== External links ==
* {{ClinicalTrialsGov|NCT03041311|Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Extensive Stage Small Cell Lung Cancer (SCLC)}}
* {{ClinicalTrialsGov|NCT02499770|Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Etoposide and Carboplatin in Extensive Stage Small Cell Lung Cancer (SCLC)}}
* {{ClinicalTrialsGov|NCT02514447|Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy}}
{{Detoxifying agents for antineoplastic treatment}}
{{Portal bar | Medicine}}
[[Category:Protein kinase inhibitors]]
[[Category:Chemotherapeutic adjuvants]]
[[Category:Pyridines]]
[[Category:Piperazines]]
[[Category:Spiro compounds]]
[[Category:Amides]]
[[Category:Guanidines]]
[[Category:CDK inhibitors]]
| |||